News for SATELLOS BIOSCIENCE INC (ICOTD)

Published at

May 22, 2025 3:00 PM

by gurufocus.com

positive

positive

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

[url="]Satellos Bioscience Inc.[/url] (TSX: MSCL, OTCQB: MSCLF) (”Satellos” or the ”Company”), a biotech company developing new small molecule therapeu

MSCL.V ICOTD

Read more →
Published at

May 7, 2025 3:00 PM

by gurufocus.com

positive

positive

Satellos to Present at the CureDuchenne FUTURES National Conference

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (”Satellos” or the ”Company”), a clinical-stage biotechnology company developing life-improving medi

MSCL.V ICOTD

Read more →
Published at

Apr 2, 2025 1:16 PM

by financialpost.com

positive

positive

Satellos to Participate in Two April Investor Conferences

TORONTO —

MSCL.V ICOTD

Read more →
Published at

Feb 10, 2025 1:07 PM

by financialpost.com

positive

positive

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

– Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the s…

MSCL.V ICOTD

Read more →
Published at

Dec 20, 2024 3:23 PM

by financialpost.com

positive

positive

Satellos Announces Closing of US$40M Public Offering

TORONTO — Satellos Bioscience Inc.

MSCL.V ICOTD CF.TO

Read more →
Published at

Dec 17, 2024 4:00 PM

by gurufocus.com

positive

positive

Satellos Announces Pricing of US$40M Overnight Marketed Public Offering

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (”Satellos” or the ”Company”), a public biotech company developing new small molecule therapeutic ap

MSCL.V ICOTD CF.TO

Read more →
Published at

Dec 17, 2024 3:23 PM

by financialpost.com

mixed

mixed

Satellos Announces Pricing of US$40M Overnight Marketed Public Offering

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSP…

CF.TO MSCL.V ICOTD

Read more →
Published at

Dec 16, 2024 10:20 PM

by investing.com

positive

positive

Satellos Announces Overnight Marketed Public Offering of Common Shares By Investing.com

Satellos Announces Overnight Marketed Public Offering of Common Shares

MSCL.V ICOTD

Read more →
Published at

Dec 11, 2024 2:00 PM

by gurufocus.com

positive

positive

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

[url="]Satellos Bioscience Inc.[/url] (TSX: MSCL, OTCQB: MSCLF) (”Satellos” or the ”Company”), a public biotech company developing new small molecule t

MSCL.V ICOTD

Read more →
Published at

Dec 11, 2024 1:06 PM

by financialpost.com

positive

positive

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

–

MSCL.V ICOTD

Read more →
Published at

Dec 3, 2024 2:00 PM

by gurufocus.com

positive

positive

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

[url="]Satellos Bioscience Inc.[/url] (TSX:MSCL, OTCQB:MSCLF) (”Satellos”), a public biotech company developing new small molecule therapeutic approaches t

MSCL.V ICOTD

Read more →
Published at

Dec 2, 2024 2:00 PM

by gurufocus.com

positive

positive

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

[url="]Satellos Bioscience Inc.[/url] (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic

MSCL.V ICOTD

Read more →
Published at

Nov 14, 2024 1:08 PM

by financialpost.com

positive

positive

Satellos Appoints Stephanie Brown to Board of Directors

TORONTO —

MSCL.V ICOTD

Read more →
Published at

Oct 15, 2022 8:58 AM

by etfdailynews.com

positive

positive

iCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below 200 Day Moving Average of $0.50

Read iCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below 200 Day Moving Average of $0.50 at ETF Daily News

MSCL.V ICOTF ICOTD ICO.V

Read more →
Published at

Jul 21, 2022 9:08 AM

by etfdailynews.com

positive

positive

iCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below Two Hundred Day Moving Average of $0.61

Read iCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below Two Hundred Day Moving Average of $0.61 at ETF Daily News

MSCL.V ICOTF ICOTD ICO.V

Read more →
Published at

Jun 21, 2022 6:18 AM

by etfdailynews.com

positive

positive

iCo Therapeutics (OTCMKTS:ICOTF) Shares Down 46.9%

Read iCo Therapeutics (OTCMKTS:ICOTF) Shares Down 46.9% at ETF Daily News

MSCL.V ICOTF ICOTD ICO.V

Read more →
Published at

May 27, 2022 4:10 PM

by investorideas.com

mixed

mixed

New Stocks and Trading Ideas: (TSX: APLI) (TSXV: MSCL) (TSXV: RVLY) (CSE: ULTA) (CSE: AGE)

Vancouver, Kelowna, Delta, BC - May 27, 2022 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its w...

PMGMF PMG.OL PMG-ME.OL MSFT MSCL.V ICOTD GMER DBGI APLIF APLI.TO ACOGF ACOG.V AAPL OAM.V

Read more →
Published at

Sep 13, 2021 1:05 PM

by marketscreener.com

mixed

mixed

Satellos Bioscience Announces Evidence for Regeneration in Severe Model of Duchenne

Satellos Bioscience Inc. , a regenerative medicine company focused on the treatment of degenerative muscle disorders, announced today core findings from additional preclinical drug development... | September 13, 2021

ICOTF ICO.V MSCL.V ICOTD

Read more →